Therefore, CB1 antagonist-based therapy has been used for the treatment of obesity, but, in spite the promising anti-obesity effects, the treatment caused severe psychiatric side effects and has been discontinued in patients [51]. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.